Evangelos Pazarentzos

2.5k total citations
19 papers, 1.1k citations indexed

About

Evangelos Pazarentzos is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Evangelos Pazarentzos has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 9 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Evangelos Pazarentzos's work include Mitochondrial Function and Pathology (5 papers), Cell death mechanisms and regulation (5 papers) and interferon and immune responses (4 papers). Evangelos Pazarentzos is often cited by papers focused on Mitochondrial Function and Pathology (5 papers), Cell death mechanisms and regulation (5 papers) and interferon and immune responses (4 papers). Evangelos Pazarentzos collaborates with scholars based in United Kingdom, United States and Saudi Arabia. Evangelos Pazarentzos's co-authors include Stefan Grimm, Christoph Datler, Ryota Iwasawa, Anne‐Laure Mahul‐Mellier, Trever G. Bivona, Anthony Lemarié, Laurence Huc, Christine T. Schwall, Nathan N. Alder and Matthew A. Gubens and has published in prestigious journals such as The EMBO Journal, Cancer Research and Oncogene.

In The Last Decade

Evangelos Pazarentzos

19 papers receiving 1.0k citations

Peers

Countries citing papers authored by Evangelos Pazarentzos

Since Specialization

Citations

This map shows the geographic impact of Evangelos Pazarentzos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evangelos Pazarentzos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evangelos Pazarentzos more than expected).

Fields of papers citing papers by Evangelos Pazarentzos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evangelos Pazarentzos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evangelos Pazarentzos. The network helps show where Evangelos Pazarentzos may publish in the future.

Co-authorship network of co-authors of Evangelos Pazarentzos

This figure shows the co-authorship network connecting the top 25 collaborators of Evangelos Pazarentzos. A scholar is included among the top collaborators of Evangelos Pazarentzos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evangelos Pazarentzos. Evangelos Pazarentzos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution 2017 ·Scientific Reports ·Vanessa D. Jönsson, (unknown), Luping Lin, Saurabh Asthana, Nikolai Matni, Victor Olivas, Evangelos Pazarentzos, Matthew A. Gubens, Boris C. Bastian, Barry S. Taylor, John C. Doyle, Trever G. Bivona	28
2	The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood–brain barrier in vitro 2016 ·Brain Research ·Chris Watson, Evangelos Pazarentzos, Mehmet Fidanboylu, Beatriz Padilla, Rachel C. Brown, Sarah Thomas	21
3	NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer 2015 ·Cell Reports ·Collin M. Blakely, Evangelos Pazarentzos, Victor Olivas, Saurabh Asthana, Jenny Yan, Irena Tan, Gorjan Hrustanovic, Elton Chan, Luping Lin, Dana S. Neel, W. H. Newton, Kathryn Bobb, Timothy Fouts, Jeffrey Meshulam, Matthew A. Gubens, David M. Jablons, Jeffrey R. Johnson, Sourav Bandyopadhyay, Nevan J. Krogan, Trever G. Bivona	143
4	Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3CβD1067V kinase domain mutation 2015 ·Oncogene ·Evangelos Pazarentzos, Petros Giannikopoulos, Gorjan Hrustanovic, (unknown), Victor Olivas, Matthew A. Gubens, Ronald Balassanian, Jonathan S. Weissman, William R. Polkinghorn, Trever G. Bivona	34
5	Adaptive stress signaling in targeted cancer therapy resistance 2015 ·Oncogene ·Evangelos Pazarentzos, Trever G. Bivona	45
6	Stefan Grimm, 1963–2014, a tragic loss for the scientific community 2015 ·Cell Death and Differentiation ·(unknown), Laurence Huc, Anthony Lemarié, Sheeba Irshad, (unknown), Christoph Datler, Evangelos Pazarentzos	2
7	Cell demise inhibited: Unexpected liaisons between mitochondria and IκΒα 2015 ·Molecular & Cellular Oncology ·Evangelos Pazarentzos	2
8	The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis 2014 ·Oncogene ·(unknown), (unknown), Ellen Stelloo, Evangelos Pazarentzos, (unknown), (unknown), Scott Harding, Abdullah M. Al‐Rubaish, (unknown), Amein K. Al‐Ali, T. A. B. Sanders, Eric O. Aboagye, Stefan Grimm	11
9	IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF ‐κB retention 2014 ·The EMBO Journal ·Evangelos Pazarentzos, Anne‐Laure Mahul‐Mellier, Christoph Datler, (unknown), (unknown), Jan Kroon, (unknown), (unknown), Abdullah M. Al‐Rubaish, Amein K. Al‐Ali, Nicholas D. Mazarakis, Eric O. Aboagye, Stefan Grimm	34
10	Mitochondrial Ca2+ influx targets cardiolipin to disintegrate respiratory chain complex II for cell death induction 2014 ·Cell Death and Differentiation ·(unknown), Christine T. Schwall, Evangelos Pazarentzos, Christoph Datler, Nathan N. Alder, Stefan Grimm	83
11	Anticancer Gene Transfer for Cancer Gene Therapy 2014 ·Advances in experimental medicine and biology ·Evangelos Pazarentzos, Nicholas D. Mazarakis	6
12	Abstract 1713: PDK1 and hexokinase 2 are downstream effectors of PTEN loss and regulate response to targeted therapies in multiple tumor types 2014 ·Cancer Research ·Evangelos Pazarentzos, Trever G. Bivona	1
13	Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma 2014 ·Cancer Research ·Collin M. Blakely, Evangelos Pazarentzos, Saurabh Asthana, Victor Olivas, Irena Tan, Timothy Fouts, Jeffrey Meshulam, Trever G. Bivona	1
14	CKMT1 regulates the mitochondrial permeability transition pore in a process that provides evidence for alternative forms of the complex 2014 ·Journal of Cell Science ·Christoph Datler, Evangelos Pazarentzos, Anne‐Laure Mahul‐Mellier, (unknown), (unknown), (unknown), Stefan Grimm	22
15	Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum 2013 ·Molecular Therapy ·Stuart Ellison, Antonio Trabalza, Veronica Tisato, Evangelos Pazarentzos, Shirley Lee, (unknown), (unknown), Sarah Morgan, Nazanin Mirzaei, Nicholas D. Mazarakis	19
16	De-ubiquitinating proteases USP2a and USP2c cause apoptosis by stabilising RIP1 2012 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Anne‐Laure Mahul‐Mellier, Christoph Datler, Evangelos Pazarentzos, (unknown), (unknown), (unknown), Stefan Grimm	20
17	De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF 2011 ·Cell Death and Differentiation ·(unknown), Evangelos Pazarentzos, Christoph Datler, Ryota Iwasawa, (unknown), Boren Lin, Stefan Grimm	65
18	Fis1 and Bap31 bridge the mitochondria–ER interface to establish a platform for apoptosis induction 2010 ·The EMBO Journal ·Ryota Iwasawa, Anne‐Laure Mahul‐Mellier, Christoph Datler, Evangelos Pazarentzos, Stefan Grimm	428
19	Specific disintegration of complex II succinate:ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction 2010 ·Cell Death and Differentiation ·Anthony Lemarié, Laurence Huc, Evangelos Pazarentzos, (unknown), Stefan Grimm	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact